<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" article-type="research-article"><front><journal-meta><journal-id journal-id-type="issn">2607-9917</journal-id><journal-title-group><journal-title>Bulletin de la Dialyse à Domicile</journal-title></journal-title-group><issn pub-type="epub">2607-9917</issn><publisher><publisher-name>RDPLF</publisher-name><publisher-loc>France</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.25796/bdd.v6i2.79033</article-id><article-categories><subj-group subj-group-type="heading"><subject>INTRODUCTION</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>EXHAUSTIVENESS</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>DESCRIPTION OF THE POPULATION</subject><subj-group subj-group-type="heading"><subject>Pre-home he</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>hemodialysis treatment</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>HOME HEMODIALYSIS PRACTICES</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>MONITORING OF DIALYSIS SESSIONS</subject></subj-group></subj-group><subj-group subj-group-type="toc-heading"><subject>VASCULAR ACCESS</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>IN-CENTER HEMODIAYSIS RESPITE</subject></subj-group><subj-group subj-group-type="toc-heading"><subject>HOME HEMODIALYSIS DISCONTINUATION</subject></subj-group></article-categories><title-group><article-title>RDPLF 2022 annual report: Profile of home hemodialysis patients in Belgium and France (synthetic raw results)</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8009-5366</contrib-id><name><surname>Verger</surname><given-names>Christian</given-names></name><address><country>France</country><email>c.verger@wanadoo.fr</email></address><xref ref-type="aff" rid="AFF-1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4256-0500</contrib-id><name><surname>Fabre</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="AFF-1"/></contrib><aff id="AFF-1">RDPLF, (Pontoise France)</aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Verger</surname><given-names>Christian</given-names></name></contrib></contrib-group><pub-date date-type="pub" iso-8601-date="2023-7-18" publication-format="electronic"><day>18</day><month>7</month><year>2023</year></pub-date><volume>6</volume><issue>2</issue><fpage>69</fpage><lpage>74</lpage><history><date date-type="received" iso-8601-date="2023-7-18"><day>18</day><month>7</month><year>2023</year></date></history><permissions><copyright-statement>Author retains copyright</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Christian Verger</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref><license-p>This work is licensed under a Creative Commons Attribution 4.0 International License.</license-p></license></permissions><self-uri xlink:href="https://bdd.rdplf.org/index.php/bdd/article/view/79033" xlink:title="RDPLF 2022 annual report: Profile of home hemodialysis patients in Belgium and France (synthetic raw results)">RDPLF 2022 annual report: Profile of home hemodialysis patients in Belgium and France (synthetic raw results)</self-uri><abstract><p>We present primary descriptive data in the form of tables and graphs for patients treated with home hemodialysis in France and French-speaking Belgium in 2022. These data were recorded in the database of the French-speaking Register of Peritoneal Dialysis and Home Hemodialysis (RDPLF).</p><p>The average age of the patients is similar in both countries: 52.7 years in France and 54.7 years in Belgium. The percentage of patients with diabetes is 25.6% in Belgium and 18.5% in France.</p><p>The majority of patients undergo daily hemodialysis 5 to 7 times per week.</p><p>Of the patients, 11% have received peritoneal dialysis in the past. Of these, 23.5% transitioned to home hemodialysis less than 3 months after stopping peritoneal dialysis, while 23.6% transitioned after 2 years of center-based or self-administered hemodialysis.</p><p>Practices differ between Belgium and France. In Belgium, a central catheter is used in 57.5% of cases, compared to 8.5% in France. For arteriovenous fistula puncture, the buttonhole technique is used in 91% of cases in Belgium and 47.8% of cases in France.</p><p>In Belgium, 70% of patients dialyze independently, while in France, 71% of patients dialyze in the presence of a family member.</p><p>The main cause of treatment discontinuation is transplantation (44% of technical dropout).</p></abstract><kwd-group><kwd>RDPLF annual report</kwd><kwd>home hemodialysis</kwd><kwd>dialyse quotidienne</kwd><kwd>RDPLF</kwd><kwd>France</kwd><kwd>Belgium</kwd></kwd-group></article-meta></front><body><sec><title>INTRODUCTION</title><p>The aim of this document is to summarize in graphic form the main descriptive elements obtained from the database of the Register of Peritoneal Dialysis and Home Hemodialysis (RDPLF) in French-speaking Belgium (Dutch-speaking Belgium does not participate in the Home Hemodialysis Register) and France (metropolitan France and overseas departments and territories) in 2022. No discussion is planned in this report, which is intended above all to provide basic documentation for dialysis teams to illustrate their work or presentations. An identical presentation was adopted for peritoneal dialysis in our last issue <xref ref-type="bibr" rid="BIBR-1">[1]</xref>. The original slides can be obtained from the RDPLF secretariat.</p><p>These tables and graphs may be freely copied, provided that the present document is cited with its DOI. The originals can also be obtained as PowerPoint files from the RDPLF secretariat.</p></sec><sec><title>EXHAUSTIVENESS</title><p>Taking as a reference the Réseau Epidemiologie Information en Néphrologie (REIN) <xref ref-type="bibr" rid="BIBR-2">[2]</xref>, which is exhaustive for France, the number of patients treated by home hemodialysis (HDD) and registered in the RDPLF represents around 45% of the total number of French patients treated by home hemodialysis. In comparison, 98% of peritoneal dialysis (PD) patients are included in the RDPLF. In Belgium, only French-speaking centers (Wallonia) participate in the HDD register of the RDPLF: taking the GNFB report <xref ref-type="bibr" rid="BIBR-3">[3]</xref> as a reference, the completeness of the RDPLF for Wallonia is 91%.</p></sec><sec><title>DESCRIPTION OF THE POPULATION</title><p>Number of prevalent patients in 2022 (treated at least 1 day): 573 patients (181 in Belgium and 392 in France); their profile is summarized in <xref ref-type="table" rid="table-1">Table I.</xref> and <xref ref-type="table" rid="table-2">Table II.</xref>.</p><p>Table I. Profile of patients treated with home hemodialysis in 2022 followed in the RDPLF</p><table-wrap id="table-1"><label>Table I.</label><caption><p>Profile of patients treated with home hemodialysis in 2022 followed in the RDPLF</p></caption><table frame="box" rules="all"><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"/><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Men</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Women</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Median age (Min-Max)</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Diabetes</bold></td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Belgium</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top">68.5%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">31.5%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">54.7 ans (14.5-91.3)</td><td colspan="1" rowspan="1" style="" align="left" valign="top">25.6%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>France</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top">67.3%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">32.7%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">52.7 ans (17.7-84.2)</td><td colspan="1" rowspan="1" style="" align="left" valign="top">18.5%</td></tr></table></table-wrap><sec><title>Pre-home he</title><p><xref ref-type="table" rid="table-2">Table II.</xref> Nephropathies monitored in the RDPLF in 2022 in patients treated with home hemodialysis</p><table-wrap id="table-2"><label>Table II.</label><caption><p>Nephropathies monitored in the RDPLF in 2022 in patients treated with home hemodialysis</p></caption><table frame="box" rules="all"><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Nephropathy</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Belgium</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>France</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Nephropathy</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Belgium</bold></td><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>France</bold></td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Vascular</td><td colspan="1" rowspan="1" style="" align="left" valign="top">12.5%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">10.1%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">System desease</td><td colspan="1" rowspan="1" style="" align="left" valign="top">4.0%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">2.1%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Congenital</td><td colspan="1" rowspan="1" style="" align="left" valign="top">4.0%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">1.1%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">Malformative</td><td colspan="1" rowspan="1" style="" align="left" valign="top">8.5%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">8.0%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Diabetes</td><td colspan="1" rowspan="1" style="" align="left" valign="top">14.8%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">10.1%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">Drug-induced</td><td colspan="1" rowspan="1" style="" align="left" valign="top">2.3%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">1.9%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Glomerular</td><td colspan="1" rowspan="1" style="" align="left" valign="top">11.9%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">27.1%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">Cystic fibrosis</td><td colspan="1" rowspan="1" style="" align="left" valign="top">14.2%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">12.5%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Uncertain</td><td colspan="1" rowspan="1" style="" align="left" valign="top">6.8%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">9.8%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">Alport-Syndrome</td><td colspan="1" rowspan="1" style="" align="left" valign="top">1.7%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">1.3%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Cardiac failure</td><td colspan="1" rowspan="1" style="" align="left" valign="top">2.8%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">0.3%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">Tumoral</td><td colspan="1" rowspan="1" style="" align="left" valign="top">1.1%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">4.0%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Interstitial</td><td colspan="1" rowspan="1" style="" align="left" valign="top">6.2%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">5.1%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">Others</td><td colspan="1" rowspan="1" style="" align="left" valign="top">9.1%</td><td colspan="1" rowspan="1" style="" align="left" valign="top">6.6%</td></tr></table></table-wrap></sec><sec><title>hemodialysis treatment</title><p><xref ref-type="table" rid="table-3">Table III.</xref> summarizes the treatment modality prior to home hemodialysis, but this does not preclude a different one prior home hemodialysis treatment. In the case of hemodialysis or transplantation, patients may have been previously treated with PD. This table should therefore be compared with the following (Table IV).</p><p>Table III. Treatment before home hemodialysis: this is the treatment immediately preceding</p><table-wrap id="table-3"><label>Table III.</label><caption><p>Treatment before home hemodialysis: this is the treatment immediately preceding</p></caption><table frame="box" rules="all"><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Pre-home hemodialysis treatment</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>Belgium</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>France</bold></td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Peritoneal dialysis</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top">7.8%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">4.6%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>In center or self hemodialysis</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top">62.7%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">71.2</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Not dialysed</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top">16.6%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">11.3</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Transplantation</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top">13.9%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">12.9</td></tr></table></table-wrap><p><xref ref-type="table" rid="table-4">Table IV.</xref>. Causes d’arrêt de DP des patients ultérieurement hémodialysés à domicile</p><table-wrap id="table-4"><label>Table IV.</label><caption><p>Causes d’arrêt de DP des patients ultérieurement hémodialysés à domicile</p></caption><table frame="box" rules="all"><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Causes of PD stops</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>Number</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>Percentages</bold></td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Diuresis recovery</td><td colspan="1" rowspan="1" style="" align="center" valign="top">1</td><td colspan="1" rowspan="1" style="" align="center" valign="top">1.7%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Transplantation</td><td colspan="1" rowspan="1" style="" align="center" valign="top">12</td><td colspan="1" rowspan="1" style="" align="center" valign="top">20.3%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Peritonitis</td><td colspan="1" rowspan="1" style="" align="center" valign="top">5</td><td colspan="1" rowspan="1" style="" align="center" valign="top">8.4%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">PD catheter problems</td><td colspan="1" rowspan="1" style="" align="center" valign="top">4</td><td colspan="1" rowspan="1" style="" align="center" valign="top">6.7</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Insufficient dialysis/UF</td><td colspan="1" rowspan="1" style="" align="center" valign="top">21</td><td colspan="1" rowspan="1" style="" align="center" valign="top">35.6%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Malnutrition</td><td colspan="1" rowspan="1" style="" align="center" valign="top">1</td><td colspan="1" rowspan="1" style="" align="center" valign="top">1.7%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Psychological intolerance</td><td colspan="1" rowspan="1" style="" align="center" valign="top">6</td><td colspan="1" rowspan="1" style="" align="center" valign="top">10.2%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Others not related to PD</td><td colspan="1" rowspan="1" style="" align="center" valign="top">8</td><td colspan="1" rowspan="1" style="" align="center" valign="top">13.6%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Diaphragmatic breach</td><td colspan="1" rowspan="1" style="" align="center" valign="top">1</td><td colspan="1" rowspan="1" style="" align="center" valign="top">1.7%</td></tr></table></table-wrap><p>History of peritoneal dialysis before home hemodialysis</p><p>Sixty-four patients (11.7%) of the 573 patients treated by home hemodialysis in 2022 had previously been treated by peritoneal dialysis (PD). This percentage is higher than that shown in Table II, as it includes patients who have had other treatment in the meantime (in-center hemodialysis or transplantation): the way the data are entered into the system means that it is not possible to know the exact path taken by patients who have changed treatment modality several times between PD and HDD.</p><p>The duration of in-center hemodialysis and/or limited care self-dialysis treatment after cessation of peritoneal dialysis and before home hemodialysis treatment varies widely  <xref ref-type="fig" rid="figure-1">Figure 1</xref>:</p><fig id="figure-1"><label>Figure 1</label><caption><p>Distribution of patients’ duration of in-center hemodialysis before home hemodialysis, for patients who were transferred from peritoneal dialysis to in-center hemodialysis before being treated with home hemodialysis</p></caption><long-desc>Figure description...</long-desc><graphic xlink:href="https://www.bdd.rdplf.org/index.php/bdd/article/download/79033/77003/178423" mimetype="image" mime-subtype="png"><alt-text>Image</alt-text></graphic></fig></sec><sec><title>HOME HEMODIALYSIS PRACTICES</title><fig id="figure-2"><label>Figure 2</label><caption><p>Number of hemodialysis sessions per week.</p></caption><graphic xlink:href="https://www.bdd.rdplf.org/index.php/bdd/article/download/79033/77003/178433" mimetype="image" mime-subtype="png"><alt-text>Image</alt-text></graphic></fig></sec><sec><title>MONITORING OF DIALYSIS SESSIONS</title><p>- In Belgium, the patient monitors the session alone in 70% of cases.</p><p>- In France, 71% of sessions are monitored by the family.</p></sec></sec><sec><title>VASCULAR ACCESS</title><p><xref ref-type="table" rid="table-5">Table V.</xref> Duration per session by number of home hemodialysis sessions per week  (Belgium and France have been grouped together as there is no significant difference).</p><table-wrap id="table-5"><label>Table V.</label><caption><p>Duration per session by number of home hemodialysis sessions per week (Belgium and France have been grouped together as there is no significant difference). </p></caption><table frame="box" rules="all"><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Number of session per week</td><td colspan="1" rowspan="1" style="" align="center" valign="top">Duration of each session</td><td colspan="1" rowspan="1" style="" align="center" valign="top">Total/ weekly</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">3</td><td colspan="1" rowspan="1" style="" align="center" valign="top">240</td><td colspan="1" rowspan="1" style="" align="center" valign="top">12 h</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">4</td><td colspan="1" rowspan="1" style="" align="center" valign="top">180</td><td colspan="1" rowspan="1" style="" align="center" valign="top">12 h</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">5</td><td colspan="1" rowspan="1" style="" align="center" valign="top">150</td><td colspan="1" rowspan="1" style="" align="center" valign="top">12,5 h</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">6 ou 7</td><td colspan="1" rowspan="1" style="" align="center" valign="top">120</td><td colspan="1" rowspan="1" style="" align="center" valign="top">12 to 14 h</td></tr></table></table-wrap><p><xref ref-type="table" rid="table-6">Table VI.</xref>. Vascular access used in home hemodialysis patients</p><table-wrap id="table-6"><label>Table VI.</label><caption><p>Vascular access used in home hemodialysis patients</p></caption><table frame="box" rules="all"><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Vascular access</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>Belgium</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>France</bold></td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Double lumen central catheter</td><td colspan="1" rowspan="1" style="" align="center" valign="top">57.8%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">8.5%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Arteriovenous fistula</td><td colspan="1" rowspan="1" style="" align="center" valign="top">42.2%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">91.5%</td></tr></table></table-wrap><p>Table VII.<xref ref-type="table" rid="table-7">Table VII.</xref> Types of arterio-venous fistula.</p><table-wrap id="table-7"><label>Table VII.</label><caption><p>Types of arterio-venous fistula.</p></caption><table frame="box" rules="all"><tr><td colspan="1" rowspan="1" style="" align="left" valign="top"><bold>Type of fistula</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>Belgium</bold></td><td colspan="1" rowspan="1" style="" align="center" valign="top"><bold>France</bold></td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Classical</td><td colspan="1" rowspan="1" style="" align="center" valign="top">8.8%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">52.2%</td></tr><tr><td colspan="1" rowspan="1" style="" align="left" valign="top">Buttonhole</td><td colspan="1" rowspan="1" style="" align="center" valign="top">91.2%</td><td colspan="1" rowspan="1" style="" align="center" valign="top">47.8%</td></tr></table></table-wrap></sec><sec><title>IN-CENTER HEMODIAYSIS RESPITE</title><p>The cumulative duration of treatment in 2022 in the cohort monitored was 154361 days; the cumulative number of days of in-center respite, all causes combined, was 7889 days, i.e. 17.5 days of in-center withdrawals per patient-year of home hemodialysis treatment. The figure is identical in Belgium and France</p></sec><sec><title>HOME HEMODIALYSIS DISCONTINUATION</title><p>-One hundred and thirty patients discontinued home hemodialysis treatment in 2022, in the cohort monitored by the RDPLF: 48 in Belgium and 82 in France. Taking the two countries together, the breakdown of reasons for leaving the technique is summarized in  <xref ref-type="fig" rid="figure-3">Figure 3</xref>, and the causes of transfer in <xref ref-type="fig" rid="figure-4">Figure 4.</xref></p><fig id="figure-3"><label>Figure 3</label><caption><p><italic>Discontinuation of home hemodialysis in 2022 (Belgium and France combined)</italic></p></caption><long-desc>Figure description...</long-desc><graphic xlink:href="https://www.bdd.rdplf.org/index.php/bdd/article/download/79033/77003/178443" mimetype="image" mime-subtype="png"><alt-text>Image</alt-text></graphic></fig><fig id="figure-4"><label>Figure 4.</label><caption><p>breakdown of reasons for transfering to in-center hemodialysis or self-dialysis</p></caption><graphic xlink:href="https://www.bdd.rdplf.org/index.php/bdd/article/download/79033/77003/178413" mimetype="image" mime-subtype="png"><alt-text>Image</alt-text></graphic></fig></sec></body><back><ref-list><title>References</title><ref id="BIBR-1"><element-citation publication-type="article-journal"><article-title>RDPLF annual report: Profile of peritoneal dialysis patients in France in 2022 synthetic raw results</article-title><source>Bull Dial Domic [Internet</source><volume>6</volume><issue>1</issue><person-group person-group-type="author"><name><surname>Verger</surname><given-names>C.</given-names></name><name><surname>Fabre</surname><given-names>E.</given-names></name></person-group><fpage>41</fpage><lpage>49</lpage><page-range>41-49</page-range><pub-id pub-id-type="doi">10.25796/bdd.v6i1.77293</pub-id><ext-link xlink:href="10.25796/bdd.v6i1.77293" ext-link-type="doi" xlink:title="RDPLF annual report: Profile of peritoneal dialysis patients in France in 2022 synthetic raw results">10.25796/bdd.v6i1.77293</ext-link></element-citation></ref><ref id="BIBR-2"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>M.</surname><given-names>Lassale</given-names></name><name><surname>C</surname><given-names>Couchoud</given-names></name></person-group><ext-link xlink:href="https://www.agence-biomedecine.fr/IMG/pdf/rapport_rein_2019_2021-10-14.pdf" ext-link-type="uri">https://www.agence-biomedecine.fr/IMG/pdf/rapport_rein_2019_2021-10-14.pdf</ext-link></element-citation></ref><ref id="BIBR-3"><element-citation publication-type=""><article-title>Rapport annuel d’activité des centres 2022 du GNFB (Groupement des Néphrologues francophones de Belgique</article-title><ext-link xlink:href="https://www.gnfb.be/" ext-link-type="uri" xlink:title="Rapport annuel d’activité des centres 2022 du GNFB (Groupement des Néphrologues francophones de Belgique">Rapport annuel d’activité des centres 2022 du GNFB (Groupement des Néphrologues francophones de Belgique</ext-link></element-citation></ref><ref id="BIBR-4"><element-citation publication-type=""><article-title>Réunion annuelle « registre et peer-review</article-title></element-citation></ref></ref-list></back></article>
